Skip to content
Search

Latest Stories

PCR tests close in NI but lateral flow test kits continue to be available in community pharmacies

Northern Ireland has announced the closure of free polymerase chain reaction (PCR) test for Covid-19 but lateral flow tests will continue to be free for patients displaying symptoms or people visiting high-risk settings and those providing close personal care.

Anyone with symptoms will no longer be required to take a PCR test, with all testing sites across Northern Ireland closing from Friday (April 22). Instead, people with symptoms have been advised to take lateral flow tests which are still available in over 500 community pharmacies across the country. Those who don’t have symptoms are no longer required to take a lateral flow test, unless they are visiting higher risk settings such as care homes, hospices or hospitals.


Deputy chief medical officer Dr Lourda Geoghegan said: “While prevalence of the virus remains high, the risk of serious illness has been significantly reduced – largely due to the success of our vaccination programme and the use of new Covid-19 treatments. As signalled in the department’s transition plan, these changes are proportionate and necessary at this stage of the pandemic.

“Transmission of Covid-19 in health and social care settings remains a risk and adds to the demands and pressures on our workforce. Anyone visiting friends or family in these settings should continue to take a lateral flow test before their visit.”

Isolation guidance for household contacts is also changing. Daily lateral flow testing is no longer advised. Household contacts are asked to be alert to symptoms and should only test if they develop symptoms. This applies to both vaccinated and unvaccinated household contacts. There is no change at this time to the guidance on isolation for positive cases.

Concluding, Dr Geoghegan said: “At this time it is important that we focus contact tracing services to help protect those at higher risk. Household contacts of a positive case are at greater risk of contracting the virus.

"Positive cases and their households will therefore continue to be provided with the necessary public health advice. It also remains vital that those at higher risk and who may be eligible for Covid-19 treatments, take a lateral flow test as soon as symptoms develop, even if symptoms are mild, as treatments should commence quickly following a positive test result.

“I urge everyone to find out if they are eligible to access lateral flow tests under the new arrangements by visiting NI Direct. We should continue to protect those at higher risk by testing if we have symptoms and isolating if we receive a positive test result.”

Test and Trace policy will be kept under review during the ongoing period of transition up until the end of June.

More For You

NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less